GlassScriptPhysician profile
Edward V Hernandez
NPI 1346263126
$3,492.18
in general payments reported to CMS, 2019-2025
22 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $83.36 · 2021: $921 · 2022: $629 · 2023: $285 · 2024: $688 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,422.39 | 2019-2025 | Clareon, Rocklatan, Total30 |
| Allergan, INC. | $558.34 | 2019-2022 | |
| Shire North American Group INC | $141.66 | 2019 | |
| Bausch & Lomb Americas INC. | $138.28 | 2022-2025 | Xiidra, Vyzulta, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.99 | 2019-2021 | |
| Oyster Point Pharma, INC. | $127.55 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $124.65 | 2019-2021 | |
| Lkc Technologies, INC. | $123.72 | 2024 | |
| Dompe US, INC. | $115.33 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $113.38 | 2024-2025 | Xdemvy |
| Abbvie INC. | $111.95 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $86.55 | 2019-2023 | |
| Amgen INC. | $52.90 | 2024-2025 | Tepezza |
| Octapharma USA, INC. | $51.53 | 2021 | |
| Biotissue Holdings INC. | $48.56 | 2019-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $43.01 | 2022 | |
| Rxsight INC | $28.79 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Horizon Therapeutics Plc | $16.85 | 2022 | |
| Astellas Pharma US INC | $16.17 | 2024 | Izervay |
| Glaukos Corporation | $14.27 | 2020 | |
| Sight Sciences, INC. | $12.79 | 2023 | Tearcare System |
| Ocular Therapeutix, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.